Logo DoctorsConnect

Your medical data, safe and secure.

Name

Dabrafenib

Description

Dabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. FDA approved on May 29, 2013.

Brands

No brand information found.